In recent years, the gene therapy field has experienced booming growth. While the FDA issued its first approved gene therapy product in 2015, and in June 2021 there were 16 approved therapies, including the three COVID-19 vaccines with emergency use authorization. The agency expects to issue 10 to 20 approvals per year by 2025. Gene therapy has grown particularly in the fields of oncology, infectious disease vaccines, and rare diseases. This white paper focuses on gene therapy uses in oncology and discusses operations and infrastructure at a cellular immunotherapy program at a National Cancer Institute (NCI)-designated comprehensive cancer center.